Appendix 4D and 1H24 financial reports
Filed with ASX · · 25 pages · English
Summary by 6ix AI
The report indicates a significant decline in both total revenue and profit compared to the previous half-year period. The company attributes the revenue decline to various macroeconomic challenges and a decrease in COVID-related testing revenue.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Australian Clinical Labs Ltd on 6ix
In the deck
Earlier from Australian Clinical Labs
- Notice of withdrawal of offer - Healius Limited
- HLS: ACCC Rejection&ACL Notice of Intention to Withdraw Offer
- Intention to withdraw takeover offer for Healius
- AXX: Accc opposes Australian Clinical Labs' proposed acquis
- Takeover offer - Healius entitlement offer
Later from Australian Clinical Labs
- FY24 Trading Update
- Appendix 4E and FY24 financial statements
- FY24 financial results investor presentation
- Notification of buy-back - ACL
- Sale of Crescent Capital shareholding
Follow Australian Clinical Labs into a list and get an email when it puts out news.
Follow Australian Clinical Labs